Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878435 | 0.80 | PDE2A (0.59) | PDE2AIDO1TDO2TRPA1 | |
| SCHEMBL63989 | 0.80 | IDO1 (0.51) | PDE2AIDO1TDO2TRPA1 | |
| SCHEMBL28453327 | 0.80 | PDE2A (0.45) | PDE2AIDO1TDO2KIF11 | |
| SCHEMBL20288912 | 0.77 | PDE2A (0.56) | PDE2AIDO1TDO2 | |
| SCHEMBL21180452 | 0.77 | PDE2A (0.56) | PDE2AIDO1TDO2KIF11 | |
| SCHEMBL14981116 | 0.72 | PDE2A (0.44) | PDE2AIDO1TDO2 | |
| SCHEMBL8160495 | 0.70 | PDE2A (0.40) | PDE2AKIF11 | |
| SCHEMBL21985627 | 0.69 | PDE2A (0.48) | PDE2AKIF11 | |
| SCHEMBL18087810 | 0.69 | PDE2A (1.00) | PDE2A | |
| SCHEMBL10938882 | 0.69 | PDE2A (0.43) | PDE2AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596885-B2 | As antiestrogenic and anti-proliferative agent | AVENTIS PHARMA S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | ROUSSEL UCLAF | 2002-06-13 | — | — | US | disclosed |
| US-6281204-B1 | ANTIESTROGENS | Roussel, Hoechst Marion (FR) | 2001-08-28 | — | — | US | disclosed |
| EP-0623140-B1 | NOVEL 19-NOR STEROIDS HAVING A THIOCARBON-CONTAINING CHAIN IN THE 11BETA POSITION, A METHOD FOR PREPARING SAME AND INTERMEDIATES THEREFOR, MEDICINAL USES THEREOF AND COMPOSITIONS CONTAINING SAID STEROIDS | HOECHST MARION ROUSSEL INC (FR) | 1998-04-22 | — | — | EP | disclosed |
| EP-0623140-A1 | NOVEL 19-NOR STEROIDS HAVING A THIOCARBON-CONTAINING CHAIN IN THE 11BETA POSITION, A METHOD FOR PREPARING SAME AND INTERMEDIATES THEREFOR, MEDICINAL USES THEREOF AND COMPOSITIONS CONTAINING SAID STEROIDS | ROUSSEL UCLAF (FR) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993013123-A1 | NOVEL 19-NOR STEROIDS HAVING A THIOCARBON-CONTAINING CHAIN IN THE 11BETA POSITION, A METHOD FOR PREPARING SAME AND INTERMEDIATES THEREFOR, MEDICINAL USES THEREOF AND COMPOSITIONS CONTAINING SAID STEROIDS | ROUSSEL-UCLAF (FR) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | HSD17B11, NR5A1, CYP19A1 | PDE2A 3343/4885IDO1 4750/4885TDO2 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.